Disclosed is the medical use of an anti-c Met antibody-cytotoxic drug conjugate. In particular, disclosed are an anti-c-Met antibody, an antigen-binding fragment of c-Met, a chimeric antibody and humanized antibody comprising the anti-c-Met antibody CDR region, and an antibody-cytotoxic drug conjugate thereof or pharmaceutically acceptable salt or solvate thereof, and the use of a pharmaceutical composition comprising the humanized anti-c-Met antibody and antigen-binding fragment and the antibody-cytotoxic drug conjugate thereof or the pharmaceutically acceptable salt or solvate thereof as an anti-hepatoma drug.